[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100542341":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":11,"centralContacts":20,"locations":26,"responsibleParty":41,"collaborators":11,"id":43,"slug":44,"hasResults":45,"nctId":46,"briefTitle":47,"officialTitle":47,"acronym":11,"eligibilityCriteria":48,"healthyVolunteers":45,"sex":49,"minAge":50,"maxAge":11,"enrollmentInfo":51,"targetDuration":11,"studyType":54,"phases":55,"briefSummary":57,"conditions":58,"keywords":11,"overallStatus":60,"whyStopped":11,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":70},{"fullName":5,"class":6},"University of Pennsylvania","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Patients with OUD, eligible for treatment with buprenorphine","EXPERIMENTAL",null,[13],"Behavioral: Telehealth for opioid use disorder treatment delivery",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":11},"BEHAVIORAL","Telehealth for opioid use disorder treatment delivery","A multi-component patient and provider facing strategy to be designed in Aim 2. Components will likely include 1) a user-friendly telehealth platform for performing all medication induction and maintenance visits, 2) integrated case management, 3) text message scheduling reminders, 4) mailed saliva drug screening tests",[9],[21],{"name":22,"role":23,"phone":24,"phoneExt":11,"email":25},"Shoshana Aronowitz, PhD","CONTACT","781-266-8571","visho@nursing.upenn.edu",[27],{"facility":5,"status":11,"city":28,"state":29,"zip":30,"country":31,"countryCode":32,"cosmosGeoPoint":33,"geoPoint":38,"contacts":39},"Philadelphia","Pennsylvania","19104","United States","US",{"type":34,"coordinates":35},"Point",[36,37],-75.16362,39.95238,{"lat":37,"lon":36},[40],{"name":22,"role":23,"phone":24,"phoneExt":11,"email":25},{"type":42,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100542341","improving-access-to-opioid-use-disorder-treatment-among-marginalized-patients-with-a-tailored-telehealth-intervention-100542341",false,"NCT06341608","Improving Access to Opioid Use Disorder Treatment Among Marginalized Patients With a Tailored Telehealth Intervention","Aim 1:\n\nInclusion Criteria\n\nFor patients:\n\nMust be 18 years old or older\n\nClinical diagnosis of opioid use disorder and\u002For mental health diagnosis\n\nMust be receiving treatment for opioid use disorder and\u002For mental health diagnosis at an outpatient community-based substance use disorder and\u002For mental health treatment program\n\nMust speak English\n\nFor providers and staff:\n\nMust be 18 years old or older\n\nMust be in a provider, clinical staff, or leadership role caring for patients with substance use disorders and\u002For mental health diagnoses\n\nMust speak English\n\nAim 2b:\n\nInclusion Criteria:\n\nMust be 18 years or older\n\nClinical diagnosis of opioid use disorder\n\nMust be receiving treatment for OUD with buprenorphine at Prevention Point Philadelphia\n\nMust speak English\n\nAim 3:\n\nPatient participants:\n\nMust be 18 years old or older\n\nClinical diagnosis of opioid use disorder\n\nMust be currently receiving in-person disorder care with buprenorphine at Prevention Point for a duration of 1-3 months OR not currently receiving disorder treatment but approved for treatment intake at buprenorphine clinic by Prevention Point clinician\n\nMust be English speaking\n\nProvider and staff participants:\n\nMust be a provider or staff member at Prevention Point Philadelphia in the buprenorphine OUD treatment program\n\nMust be involved in the care of at least one patient enrolled in the pilot trial\n\nMust be English speaking","ALL","18 Years",{"count":52,"type":53},60,"ESTIMATED","INTERVENTIONAL",[56],"NA","The goal of this pilot trial is to develop and test a telehealth intervention for OUD care delivery and refine measurement strategies.\n\nThe specific aims are to: 1) identify components of an effective telehealth intervention and barriers to implementation, 2) partner with an advisory board of OUD treatment stakeholders from different settings to develop a telehealth intervention for OUD treatment with buprenorphine, and 3) conduct a pilot trial of the telehealth intervention for OUD treatment.\n\nThe investigators will enroll 60 patients, 30 individuals who are currently enrolled in in-person OUD treatment with buprenorphine, with a treatment episode duration of 1-3 months, and 30 individuals who are not currently receiving OUD treatment but approved for treatment intake at buprenorphine clinic by an OUD treatment clinician, to receive the telehealth for OUD care delivery intervention. The investigators will measure clinical, implementation, and patient satisfaction outcomes.",[59],"Opioid Use Disorder","NOT_YET_RECRUITING","2026-06-08",{"date":63,"type":64},"2026-06-09","ACTUAL",{"date":66,"type":53},"2026-09-15",{"date":68,"type":53},"2028-04",{"name":5,"class":6},1]